EP
BCRX icon

Essential Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Essential Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.8K Sell
1,475
-2,411
-62% -$21.8K 0.01% 1026
2026
Q1 		$37K Sell
3,886
-160
-4% -$1.24K 0.01% 683
2025
Q4 		$31.6K Sell
4,046
-997
-20% -$7.21K 0.01% 743
2025
Q3 		$38.3K Sell
5,043
-1,501
-23% -$12.5K 0.01% 676
2025
Q2 		$58.6K Buy
+6,544
New +$60.9K 0.02% 440

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Essential Partners's BCRX Position: Q2 2026 in Review

Essential Partners reduced its BioCryst Pharmaceuticals (BCRX) stake by 62% in Q2 2026, selling an estimated $21.8K and leaving 1,475 shares worth $14.8K. The position accounts for 0.01% of the portfolio, ranked #1026.

Essential Partners first reported a position in BCRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $58.6K in Q2 2025. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Essential Partners held 1,475 shares of BioCryst Pharmaceuticals worth $14.8K as of Q2 2026.
  • Essential Partners sold 2,411 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $21.8K.
  • BioCryst Pharmaceuticals made up 0.01% of Essential Partners's portfolio in Q2 2026, its #1026 holding.
  • Essential Partners first reported a position in BioCryst Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's BioCryst Pharmaceuticals position peaked at $58.6K in Q2 2025.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.